licogliflozin (LIK066) / Novartis 
Welcome,         Profile    Billing    Logout  
 5 Diseases   1 Trial   1 Trial   89 News 


12»
  • ||||||||||  Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Zynquista (sotagliflozin) / Lexicon Pharma, licogliflozin (LIK066) / Novartis
    FAILURE OF SGLT-2 INHIBITOR IN THE CONTEXT OF NEW ILEAL CONDUIT FORMATION () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1068;    
    This scenario could be an indication to use dual novel SGLT1/2 inhibitors like sotagliflozin and licogliflozin. More clinical trials are needed to validate this hypothesis.
  • ||||||||||  licogliflozin (LIK066) / Novartis
    Journal:  Cu Single Atom Nanozyme Based High-Efficiency Mild Photothermal Therapy through Cellular Metabolic Regulation. (Pubmed Central) -  Oct 21, 2022   
    In this work, Cu SAzyme presents extraordinary multienzyme activities to induce reactive oxygen species (ROS) storm formation, which can damage the existing HSPs in cancer cells. Through a two-pronged strategy of SGLT inhibitor and ROS storm, LIK066-loaded Cu SAzyme shows high efficiency for comprehensive removal of HSPs to realize mild PTT.
  • ||||||||||  licogliflozin (LIK066) / Novartis
    Journal:  Licogliflozin effective in PCOS treatment. (Pubmed Central) -  Nov 12, 2021   
    Further studies are needed to clarify their role in weight management. No abstract available
  • ||||||||||  licogliflozin (LIK066) / Novartis
    Trial completion:  Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients (clinicaltrials.gov) -  Feb 12, 2020   
    P2,  N=107, Completed, 
    Not yet recruiting --> Recruiting | Trial primary completion date: May 2020 --> Mar 2022 Active, not recruiting --> Completed
  • ||||||||||  Biomarker, Review, Journal:  Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018. (Pubmed Central) -  Feb 7, 2020   
    Of these, six candidates (MDCO-216, TRV027, ubenimex, sodium nitrite, losmapimod, and bococizumab) were dropped for lack of clinical efficacy, the other six for strategic or unspecified reasons...Four candidate developments (OPC-108459, ONO-4232, GSK-2798745, and TAK-536TCH) were run without biomarkers, which could be used as surrogate endpoints in the 12 cardiovascular drugs discontinued from 2016 to 2018. This review will be useful for those involved in the field of drug discovery and development, and for those interested in the treatment of cardiovascular disease.
  • ||||||||||  licogliflozin (LIK066) / Novartis
    Enrollment closed:  Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients (clinicaltrials.gov) -  Sep 26, 2019   
    P2,  N=107, Active, not recruiting, 
    Studies of longer duration and in combination with drugs that have different mechanisms of action are needed to define the role of licogliflozin as a therapeutic option for NASH. Recruiting --> Active, not recruiting
  • ||||||||||  licogliflozin (LIK066) / Novartis
    Trial completion date, Trial primary completion date:  Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients (clinicaltrials.gov) -  Jun 15, 2018   
    P2,  N=110, Recruiting, 
    Recruiting --> Completed Trial completion date: Apr 2019 --> Sep 2019 | Trial primary completion date: Apr 2019 --> Sep 2019
  • ||||||||||  licogliflozin (LIK066) / Novartis
    Trial completion, Trial completion date, Trial primary completion date:  Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=53, Completed, 
    Trial primary completion date: Nov 2017 --> Mar 2018 | Trial completion date: Nov 2017 --> Mar 2018 Recruiting --> Completed | Trial completion date: Nov 2017 --> Jan 2018 | Trial primary completion date: Nov 2017 --> Jan 2018